Is sermorelin FDA-approved? Status, evidence and risks (October 2026)

Status at a glance

The Geref history, and why it matters now

Sermorelin acetate was sold in the U.S. as GEREF. That product was discontinued. In a Federal Register notice on March 4, 2013, FDA stated: “FDA has determined under § 314.161 that GEREF (Sermorelin Acetate) injection, 0.5 mg base/vial and 1.0 mg base/vial, and GEREF (Sermorelin Acetate) injection, 0.05 mg base/amp, were not withdrawn for reasons of safety or effectiveness” (78 FR 14096).

That determination is the hinge of the compounding debate. One 503A route lets pharmacies use a bulk substance that is a component of an FDA-approved drug, and clinics argue sermorelin qualifies because of Geref. FDA has not said so on any page we read, and sermorelin is in none of FDA’s interim categories. We report the argument; we do not settle it.

Human evidence

Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue: it prompts the pituitary to release the body’s own growth hormone. Geref’s approval rested on clinical data in its labelled setting. For the uses clinics sell today — adult anti-ageing, body composition, sleep and recovery — the evidence is thin. We have not re-read the clinical literature for this update and cite no trial. A rise in growth hormone or IGF-1 on a blood test is a biomarker, not proof that you will feel or look different.

Animal and laboratory evidence

Much of the physiology behind GHRH analogues comes from animal and laboratory research. It explains how sermorelin acts; it does not show the marketed benefits in healthy adults.

Risks

The main risks are those of any compounded injectable: the product is not FDA-approved, the FDA does not check its quality before it reaches you, and sterility and dose depend on the pharmacy. Ask the prescriber what will be monitored and what result would mean stopping. See sermorelin safety for questions to ask.

Legal sourcing: who can supply it

If you use sermorelin, the minimum standard is a licensed clinician and a named, state-licensed pharmacy that will tell you its legal basis for compounding it. Because FDA has not confirmed that basis, ask in writing. See how to verify a peptide provider and peptide legality.

The lawful route for a prescription peptide in the United States is a licensed clinician who examines you and writes a prescription, filled by a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility that is allowed to use that substance. Websites that sell peptides “for research use only” or “not for human consumption” are not a lawful source of medicine for people. On August 24, 2026, FDA sent warning letters to five such sellers — Peptide Partners, Peak Performance Peptides, Royal Peptides, NuScience Peptides and Tex Peptides — calling their products unapproved new drugs. FDA wrote that the research-use labels did not change its view because the websites showed the products were meant for human use.

October 2026: what changed

• April 2026 — Category 2 withdrawals. FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604, injectable GHK-Cu and other peptides off its Category 2 list after the nominators withdrew them. FDA lists them as “nominated but withdrawn” (page current as of April 22, 2026). They were not moved into Category 1.
• July 23–24, 2026 — advisory committee. FDA’s Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon. FDA staff proposed not adding BPC-157 or TB-500. A law-firm account reports the committee voted 8–6 (one abstention) to recommend BPC-157, KPV and TB-500 (McDermott, July 27, 2026). A vote is advice; FDA has taken no final action.
• October 14–15, 2026 — interim access policy under White House review. The OIRA review site lists “Interim Access Policy for Compounding Using Certain Peptides” from HHS/FDA (RIN 0910-ZD94, stage: Notice), received October 14, 2026 and pending review; no text has been published (reginfo.gov). Reuters reported the filing on October 15 (Reuters), and the AP, citing two people, said it would let pharmacies make some popular peptides, including BPC-157. Which peptides, on what terms and from when are not public. Our running table: peptide legal status 2026.

For sermorelin: it was not part of the April withdrawals or the July PCAC meeting, so its position is unchanged. Whether the interim access policy touches sermorelin is unknown. For prices, see sermorelin cost; we have not verified any.

New this month: what is known about FDA’s peptide interim access policy · a status table for 16 peptides (FDA and WADA).